How it Works
This novel drug candidate is designed for the liposomal delivery of the anti-cancer drug doxorubicin directly to a tumor, with a glutathione coating added to exploit active endogenous transporters, allowing the drug to cross the blood-brain barrier.
Doxorubicin is an anthracycline that inhibits the growth of many cancerous cell lines, including glioblastoma and breast cancer cell lines. It is among the most widely used anti-cancer agents.
Phase 2 clinical studies have been prepared, using a validated DRP companion diagnostic in patients with brain metastases from breast cancer and recurrent glioblastoma multiforme (GBM).
2X-111 has been granted orphan drug designation by the U.S. Food and Drug Administration.
In a prior clinical trial conducted without a DRP, 2X-111 demonstrated encouraging efficacy and safety. Observed response rates in this Phase 2 study in brain metastases from breast cancer included 67% disease control. Use of the validated DRP for 2X-111 in future trials is expected to result in improved efficacy.
A molecular model of doxorubicin. 2X-111 is is designed for the liposomal delivery of doxorubicin directly to a tumor.